<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Prazosin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00457</strong>&#160; (APRD00020)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Prazosin is a selective &#945;-<sub>1</sub>-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. &#945;<sub>1</sub>-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with &#946;-blockers in the preoperative management of signs and symptoms of pheochromocytoma.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00457/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00457/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00457.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00457.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00457.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00457.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00457.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00457">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Prazosina</td><td>Spanish</td><td>INN</td></tr><tr><td>Prazosine</td><td>French</td><td>INN</td></tr><tr><td>Prazosinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Prazosin Hydrochloride</strong>
          <div class="cas">19237-84-4</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000329/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000329/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: WFXFYZULCQKPIP-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 419.136031924</li>
              <li>Average Mass: 419.862</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000329">DBSALT000329</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Hypovase</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Minipress</td><td>Pfizer</td></tr><tr><td>Minipress Xl</td><td>Pfizer</td></tr><tr><td>Pressin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vasoflex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Minizide</td><td>prazosin + polythiazide</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/adrenergic-alpha-1-receptor-antagonists">Adrenergic alpha-1 Receptor Antagonists</a></li>
<li><a href="/mesh/adrenergic-alpha-antagonists">Adrenergic alpha-Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>19216-56-9</td></tr><tr><th>Weight</th><td>Average: 383.4011<br>Monoisotopic: 383.159354185</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>21</sub>N<sub>5</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>IENZQIKPVFGBNW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-{4-[(furan-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthyridines</td></tr><tr><th>Subclass</th><td>Quinazolines</td></tr><tr><th>Direct parent</th><td>Quinazolinamines</td></tr><tr><th>Alternative parents</th><td>Anisoles; Aminopyrimidines and Derivatives; Alkyl Aryl Ethers; Primary Aromatic Amines; Piperazines; Diazinanes; Furans; Tertiary Carboxylic Acid Amides; Tertiary Amines; Polyamines; Carboxylic Acids; Enolates</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; aminopyrimidine; alkyl aryl ether; 1,4-diazinane; piperazine; pyrimidine; primary aromatic amine; benzene; tertiary carboxylic acid amide; furan; tertiary amine; carboxamide group; polyamine; carboxylic acid derivative; ether; carboxylic acid; enolate; amine; organonitrogen compound; primary amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with &#946;-blockers in the preoperative management of signs and symptoms of pheochromocytoma. </td></tr><tr><th>Pharmacodynamics</th><td>Prazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Prazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Prazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, <i>in vitro</i>, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Prazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Prazosin results from a decrease in systemic vascular resistance and the parent compound Prazosin is primarily responsible for the antihypertensive activity.</td></tr><tr><th>Mechanism of action</th><td>Prazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.</td></tr><tr><th>Absorption</th><td>Well-absorbed from gastrointestinal tract; bioavailability is variable (50 to 85%).</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>97%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic. Several metabolites have been identified in humans and animals (6- O -demethyl, 7- O -demethyl, 2-[1-piperazinyl]-4-amino-6, 7-dimethoxyquinazoline, 2,4-diamino-6,7-dimethoxyquinazoline).</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Prazosin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00691">2,4-diamino-6,7-dimethoxyquinazoline</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/712">Details</a></td></tr><tr><td>Prazosin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00766">6-O-demethyl,7-O-demethyl,2-[1-piperazinyl]-4-amino-6,7-dimethoxyquinazoline</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/787">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man.</td></tr><tr><th>Half life</th><td>2-3 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9479</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8298</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7193</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5747</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6405</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8773</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7641</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7577</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8434</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9278</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9685</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9169</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7608</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8049</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5581
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9199
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9818
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3304 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8352
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8489
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pfizer laboratories div pfizer inc</li>
<li>American therapeutics inc</li>
<li>Clonmel healthcare ltd</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mylan pharmaceuticals inc</li>
<li>Purepac pharmaceutical co</li>
<li>Sandoz inc</li>
<li>Watson laboratories inc</li>
<li>Pfizer inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://BASF%20Corp.">BASF Corp.</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li>Heartland Repack Services LLC</li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.kramernovis.com">Kramer-Novis</a></li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>1 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>2 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>Beta-Blockers such as betaxolol may enhance the orthostatic hypotensive effect of Alpha1-Blockers such as prazosin. The risk associated with ophthalmic products is probably less than systemic products. Exercise caution if an alpha1-blocker is added to existing beta-blocker therapy. Monitor for hypotension during first few days of concomitant therapy. A priori reduction in alpha1-blocker (especially systemic) dose may be warranted. Administering the first dose of systemic agents at bedtime may help minimize risk of severe hypotension. The risk associated with the use of ophthalmic products in either interacting group is probably less than that associated with systemic agents. If the alpha1-blocker is being used to treat BPH, consider using tamsulosin since its alpha1-A selectivity is least likely to cause hypotension.</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB06695">Dabigatran etexilate</a></td><td>P-Glycoprotein inducers such as prazosin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Prazosin increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Tadalafil may enhance the hypotensive effect of Prazosin. Monitor for hypotension during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Prazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Prazosin, may occur. Monitor for hypotension during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Risk of hypotension at the beginning of therapy</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid natural licorice.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>